Highlights Glenmark Pharmaceuticals Limited

Equities

GLENMARK

INE935A01035

Market Closed - NSE India S.E. Other stock markets 07:42:30 2024-04-30 am EDT			5-day change	1st Jan Change
1,057 ^INR	-1.30%		+1.72%	+23.80%

Apr. 29	Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines	MT
Apr. 25	Glenmark Lifesciences' Net Profit Slides in Fiscal Q4	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Glenmark Lifesciences' Net Profit Slides in Fiscal Q4	Apr. 25	MT
Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited from Glenmark Pharmaceuticals Limited.	Mar. 11	CI
India's Glenmark Pharma posts loss for Q3 as remediation cost weighs	Feb. 14	RE
Glenmark Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Glenmark Pharma, Pfizer Launch Atopic Dermatitis Oral Treatment in India	Jan. 31	MT
Glenmark Pharmaceuticals Limited Partners with Pfizer to Launch Abrocitinib in India	Jan. 31	CI
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	Jan. 24	MT
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO	Jan. 23	RE
Glenmark Pharmaceuticals Limited Launches Biosimilar of the Popular Antidiabetic Drug, Liraglutide, for the First Time in India	Jan. 02	CI
Glenmark Pharmaceuticals Introduces Anti-Diabetic Drug Liraglutide in India	Jan. 03	MT
Glenmark Pharmaceuticals Swings to Loss in Fiscal Q2; Shares Slide 5%	Nov. 14	MT
India's Glenmark Pharma posts Q2 loss on exceptional legal costs	Nov. 10	RE
Glenmark Pharmaceuticals Limited Receives ANDA Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg	Nov. 06	CI
India's Glenmark Life Sciences posts Q2 profit rise on API boost	23-10-20	RE
Glenmark Pharma Launches Diabetes Control Drug in India	23-10-18	MT
Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-Morbidities	23-10-17	CI
Glenmark Pharmaceuticals Gets USFDA Nod for Apremilast Tablets	23-10-17	MT
Glenmark Pharmaceuticals Receives ANDA Approval for Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg	23-10-16	CI
Glenmark Pharma Unit Licenses Antibody Portfolio to Astria Therapeutics	23-10-12	MT
Glenmark Pharmaceuticals to Divest Majority Stake in Glenmark Life Sciences for INR56.5 Billion	23-09-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Glenmark Pharmaceuticals Limited

Equities

GLENMARK

INE935A01035

Highlights

Filters